XLOXilio Therapeutics, Inc.

$28M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$15M-652.3% margin

Net Income

-$14M-619.5% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$75M

Total Liabilities

$54M

Stockholders' Equity

$21M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$15M	-$17M	+15.0%
Net Income	-$14M	-$17M	+16.3%

XLO Q3 2024 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena